European PR & Communications Summit for Pharmaceutical, Biotech and Medical Device

29-30 March 2010, Bayer Schering Pharma Headquarters Berlin, Germany.
The pharmaceutical/biotech/medical device industry is undergoing significant transformations and the need for meaningful and cost-effective communications is greater than ever. Changes in the political, economic and regulatory environments coupled with revolutions in technology are creating an exciting, yet challenging, atmosphere in which companies must operate. Communications executives in Europe have the ability to embrace these changes and use them as an opportunity to help ensure successful market positions, brands and corporate images. Based on the success of last year's event, ExL Pharma is pleased to bring you the 2nd Annual European Public Relations & Communications Summit. This conference promises to provide industry professionals with concrete tools for enhancing both internal and external communications. Through sessions covering a broad range of topics including social media, the industry's reputation, working effectively with the media and much more, attendees will gain practical strategies for success. Offering ample networking and learning opportunities, this event is sure to be highly interactive and informative.

This conference is designed for executives from pharmaceutical, biotech, medical device and generic companies with responsibilities in the following areas:

  • Corporate Communications
  • Public Relations
  • Media Relations
  • Marketing
  • Product/Brand Management
  • Advocacy
  • Promotions
  • Foundation Work
  • Community Relations
  • Internal Communications
  • Public Affairs
  • Public Policy
  • Government Affairs
  • Strategic Alliances
  • Commercial Analysis
  • Legal/Corporate-Counsel

This program is also of interest to:

  • PR Agencies
  • Consultants
  • Marketing Service Providers
  • Associations/Consortiums
  • Community Service Organizations
  • Advertising Agencies

For further information and registration, please visit:
http://www.exlpharma.com/events/european-pr-communications-summit-pharmaceutical-biotech-and-medical-device

About ExL Pharma
ExL Pharma, a division of ExL Events, Inc., is an international leader in developing innovative, educational events that serve the healthcare community and allied professionals. Behind our diverse conference portfolio, our experienced team conducts extensive market research and targeted outreach. The results translate into innovative, high-quality conference events designed to exceed the dynamic informational needs of the healthcare community.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Disparities in United States COVID-19 vaccine dist…

When reports showed COVID-19 vaccination rates were lower among racial/ethnic minority groups, most discussions focused on mistrust and misinformation among these populat...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

GSK signs agreement to support pandemic preparedne…

GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European Commission's (EC) Health Emergency Preparedness and Response Authority (HERA) for t...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...